The current HCV therapy includes pegylated alpha interferon (IFN-α), ribavirin and one of the recently approved HCV NS3 protease inhibitors Boceprevir and Telaprevir for genotype I infections [4], [5], and IFN-α and ribavirin for infections with other genotypes. This evidence concerns the gene KRAS and infection.